-
03.19.2019 | AMR Conference in Berlin: Call for better incentives
“We need the political willingness to put money on the table”, said Peter Beyer, Senior Advisor at the World Health Organisation at the “Novel Antimicrobials and AMR Diagnostics 2019” conference in Berlin, which attracted around 330 stakeholders from small and large pharmaceutical companies, the FDA, major global funding initiatives and financiers such as CARB-X, FIND, JPIAMR, GARDP, ENABLE or Novo’s REPAIR impact fund etc., and from applied sciences and national hubs. At the conference, it was announced that the German Federal Ministry of Education and Research was joining the CARB-X partnership, committing 39 million euros to CARB-X.
-
03.14.2019 | Germany joins the CARB-X partnership: Invests €39M to incentivise the early development of antibiotics, vaccines, and diagnostics to combat AMR
EUROPEAN BIOTECHNOLOGY | Germany has joined the CARB-X partnership. Under the four-year agreement signed earlier this week with the Federal Ministry of Education and Research (BMBF), Germany will invest €39m to incentivise the early development of antibiotics, vaccines, and diagnostics to combat resistance to antimicrobials (AMR).Germany will provide an additional €1m in direct support to a consortium of the German Center for Infection Research (DZIF, Braunschweig), the Federal Institute for Vaccines and Biomedicines (PEI, Langen) and the Federal Institute for Drugs and Medical Devices (BfArM, Berlin), which is set to join the CARB-X Global Accelerator Network. The move is part of Germany's overall €500M R&D budget in the next 10 years to fight against antimicrobial resistance.
-
03.14.2019 | Backgrounder: Why CARB-X is building its accelerator network in Europe?
EUROPEAN BIOTECHNOLOGY | CARB-X has expanded its accelerator network, with a focus on building the network particularly in Europe. CARB-X Executive Director Kevin Outterson explains in this Q&A how CARB-X is building its portfolio of antibacterial products and why it is essential for CARB-X to partner with world-class accelerators to support the great science in the portfolio.
-
03.05.2019 | Can Netflix show Americans how to cut the cost of drugs?
NEW YORK TIMES | Can American healthcare learn something from Netflix and Hulu, that charge flat subscription fees no matter how many movies you watch. Some countries have negotiated deals with pharmaceutical companies to get all the brand name drugs they can use for several years for a flat fee. In her opinion piece, journalist Tina Rosenberg argues that the United States can learn a lot from economic models that exist in other countries, companies and therapy areas, including in the evolving economic model for antibacterial products to prevent, diagnose and treat drug-resistant infections. Could the emerging push-and-pull-incentive economic model hold some of the answers?
-
03.04.2019 | T2 lands breakthrough devices designation for panel that can detect 13 resistance genes
MEDICAL DEVICE DAILY | T2 Biosystems has won breakthrough device designation for the T2resistance panel, an exciting new diagnostic under development with the help of CARB-X, which can detect 13 resistance genes from both Gram-positive and Gram-negative pathogens from a single patient blood sample. The device, if approved and used in clinical setting, could radically improve the diagnosis of life-threatening bacterial infections, speed and improve the delivery of treatment to patients, and save money and precious time. Currently it can take days to provide a reliable diagnosis. The 13 genes identified include those largely resistant to antimicrobial drugs that are crucial in the treatment of bacterial infections, including carbapenems, vancomycin and penicillin.
-
03.04.2019 | Vaccines work – for superbugs too
MEDICAL PRESS | We need to supercharge the global response to anti-microbial resistance. Developing new vaccines against superbugs would help build the world’s arsenal in the fight against drug resistance. Wellcome Trusts’ Ed Whiting calls for more effort to be directed toward the research and development of new vaccines, and he calls out CARB-X as a way to channel investment into R&D that will produce urgently needed vaccines that could save lives.
-
02.26.2019 | AMR network CARB-X expands its global reach with accelerators to boost support for its growing portfolio
EUROPEAN BIOTECHNOLOGY | CARB-X has added six new accelerator partners to its Global Accelerator Network to increase support for development research projects it funds to fight the rise of drug-resistant bacteria. The new accelerators located in the US, Denmark, Switzerland, Germany, UK and India join CARB-X’s existing accelerator partners, CLSI, MassBio and RTI International in the US and the Wellcome Trust in the UK to provide scientific, technical and business support to the growing numbers of CARB-X-funded antibacterial research projects. The new accelerator partners are BaselArea.Swiss, BioInnovation Institute (BII), Centre for Cellular and Molecular Platforms (C-CAMP), Foundation for Innovative New Diagnostics (FIND), German Center for Infection Research (DZIF), and Institute for Life Sciences Entrepreneurship (ILSE).
-
02.25.2019 | Why we need public-private partnerships in drug R&D
PHARMA BOARDROOM | Pierre Meulien, Executive Director of the Innovative Medicines Initiative (IMI) in Europe, outlines the value of public-private partnerships in drug research and development and highlights areas where these collaborations are proving their worth in overcoming some of the most challenging threats to our health.
-
02.25.2019 | Kean University’s ILSE joins the CARB-X accelerator network in fight against drug resistant superbugs
KEAN UNIVERSITY | ILSE joins the CARB-X Global Accelerator Network, building on New Jersey’s history of entrepreneurship and innovation, which includes the discovery of the antibiotic streptomycin in the 1940s.
-
02.18.2019 | Free Resource Against Infections – Novartis contributes to PEW’s SPARK open-science database
The open-access Shared Platform for Antibiotic Research and Knowledge (SPARK) created by the Pew Charitable Trusts just got a boost from Novartis, which has shared data from its antibiotic research programs. This comes on the heels of biopharmaceutical company Achaogen’s recent commitment to give SPARK data from its own discontinued antibiotic research program.
-
02.18.2019 | Viral, bacterial diagnostics bolster antimicrobial stewardship
HEALIO Infectious Diseases in Children | Pediatricians and other health professionals need better, faster and cost-effective diagnostic tests to diagnose bacterial and viral infections in children, many health professionals say. Too often antibiotics are prescribed when not needed, contributing to the rise of drug-resistance, and health problems are not addressed adequately or quickly enough because high-quality rapid diagnostics are not available in many clinical settings. Many new diagnostics are in development.
-
02.12.2019 | Antimicrobial resistance: The Ten Commandments – Two Years On – A Response
MICROBIOLOGIST | Two years after Lord Jim O’Neill led the UK AMR review to its final report, which recommended 10 Commandments to address AMR, the Society for Applied Microbiology takes stock of the achievements, and the challenges that remain. While progress has been made in the fight against the rise of superbugs, more improvements and action are urgently needed. The Microbiologist special report, published in December 2018, includes a chapter on Commandment 8: Establish a Global Innovation Fund for early-stage and non-commercial research, written by Kevin Outterson, CARB-X Executive Director.
-
02.05.2019 | Twenty new drugs in pipeline to fight superbugs
THE TIMES | There is hope that new antibiotics and other life saving drugs will be delivered to patients in the coming years, according to Kevin Outterson, Executive Director of CARB-X, in an interview with The Times. There are exciting new scientific approaches and promising new drugs progressing in CARB-X’s global pipeline.
-
01.29.2019 | We can win the war on superbugs but only with the right investment
THE TELEGRAPH | The UK is showing the world that it is leading by example with its pilot project to reward drug developers that deliver new urgently needed antibiotics to the health system. It is a plan that could help incentivize innovation and complement the work of CARB-X and others to fund and support the development of new AMR products. Now it is time for other countries and world leaders to step up as well to commit to resource this approach fully. It is time to show that there is political will at the highest level to stop the rise of superbugs. A commentary by Wellcome Trust’s Jeremy Knox.
-
01.17.2019 | CARB-X has awarded ContraFect additional funds to support the development of its lysin therapeutics
GLOBE NEWSWIRE | CARB-X has awarded ContraFect additional funds to support the continued development of its lysin therapeutics program to treat serious invasive infections caused by antibiotic-resistant Pseudomonas aeruginosa (P. aeruginosa). This is an increase to the original CARB-X award announced in March 2017. The initial award was $1.1 million, with the possibility of $1 million more if certain project milestones were met. Upon achievement of those milestones, CARB-X decided earlier this year to award the previously announced option of $1 million, plus an additional $1.3 million to continue to support the development of the project.
-
01.08.2019 | Forge awarded next stage of product funding from CARB-X for its novel IV/Oral LpxC antibiotic
PR NEWSWIRE | Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes has received notice from CARB-X that based on the achievement of technical milestones, CARB-X will proceed with the next stage of product funding for Forge's novel IV/Oral LpxC antibiotic to treat urinary tract infections including MDR infections caused by CRE and ESBL. In March 2017, Forge was one of the first recipients of a cost-sharing award to advance promising antibacterial candidates through the early stages of development. Forge was initially awarded $4.8M over 15 months from CARB-X and as a second stage, will receive up to $4M million in additional support.
-
01.02.2019 | Fight against superbugs is crucial to the the US’s biodefense
PEW TRUSTS | In this insightful Q&A, Rick Bright, director of the Biomedical and Advanced Research and Development Authority (BARDA), explains why the fight against superbugs is so crucial to not only public health in the US, but also to national security. Drug resistant superbugs complicate wounds, exacerbate casualties associated with natural and manmade emergencies, and can be used as weapons. Bright highlights the steps the US is taking as part of the National Biodefense Strategy to reduce the spread of superbugs domestically and internationally, and to accelerate the development of new drugs, diagnostic tests and vaccines. BARDA is a CARB-X founder and funding partner.
Toggle navigation
